Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

OPGN - Opgen Inc


Previous close
1.945
0   0%

Share volume: 92,212
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.94
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
23%
Profitability 43%
Dept financing 16%
Liquidity 42%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.94
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$26.56
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
1.349 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Oliver Schacht
Region: US
Website: http://opgen.com/
Employees: 65
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.

Recent news